Claims
- 1. A compound of the formula:
- 2. A pharmaceutical composition for treating abnormal angiogenesis in an animal, comprising:
a therapeutically effective amount of an agent wherein said agent is selected from the compounds of claim 1, said agent being capable of altering an aspect of MetAP2 metabolism or structure in said animal so as to result in treatment of said abnormal angiogenesis; and a pharmacuetically acceptable carrier.
- 3. The composition of claim 2 wherein said agent is a compound of the formula:
- 4. A pharmaceutical composition for treating an immune reaction which results in pathology in an animal, comprising:
a therapeutically effective amount of an agent wherein said agent is selected from compounds of claim 1, said agent being capable of altering an aspect of MetAP2 metabolism or structure in said animal so as to result in treatment of said immune reaction; and a pharmaceutically acceptable carrier.
- 5. The composition of claim 4 wherein said agent is a compound of the formula:
Parent Case Info
[0001] This application is a divisional of application U.S. Ser. No. 09/093,448, filed Jun. 8, 1998, which claims the benefit of U.S. provisional application, U.S. Ser. No. 60/049,159, filed Jun. 9, 1997, each of which is incorporated herein by reference.
Government Interests
[0002] The U.S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of Grant No. CA09112 awarded by the National Cancer Institute.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60049159 |
Jun 1997 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09093448 |
Jun 1998 |
US |
Child |
09813555 |
Mar 2001 |
US |